Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Klinique Medical Clinic PCLBKK:KLINIQ 89 Debt-to-EBITDA is 0.65 as of Mar. 2026, which is 23% below its 10-year median of 0.84. GuruFocus rates BKK:KLINIQ with a GF Score™ of 89/100 and a GF Value™ of ฿44.59 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 70 Personal Services companies, The Klinique Medical Clinic PCL ranks better than 78.57% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for The Klinique Medical Clinic PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:KLINIQ'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.74 Med: 0.84 Max: 0.94
Current: 0.74
During the past 7 years, the highest Debt-to-EBITDA Ratio of The Klinique Medical Clinic PCL was 0.94. The lowest was 0.74. And the median was 0.84.
BKK:KLINIQ's Debt-to-EBITDA is ranked better than 78.57% of 70
companies
in the Personal Services industry
Industry Median: 2.32
vs BKK:KLINIQ: 0.74
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The Klinique Medical Clinic PCL Debt-to-EBITDA Related Terms
The Klinique Medical Clinic PCL Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Klinique Medical Clinic PCL Debt-to-EBITDA Chart
BKK:KLINIQ vs ROL, SCI, HRB: Debt-to-EBITDA Comparison
For the Personal Services subindustry, The Klinique Medical Clinic PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Klinique Medical Clinic PCL Debt-to-EBITDA vs Personal Services Industry
For the Personal Services industry and Consumer Cyclical sector, The Klinique Medical Clinic PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where The Klinique Medical Clinic PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
The Klinique Medical Clinic PCL (BKK:KLINIQ) has a Debt-to-EBITDA of 0.65 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Klinique Medical Clinic PCL. This is 23% below median its historical median of 0.84. Over the past decade, The Klinique Medical Clinic PCL's Debt-to-EBITDA has ranged from 0.74 to 0.94. According to the industry distribution chart, The Klinique Medical Clinic PCL ranks #15 out of 70 companies in the Personal Services industry, placing it in the top 21.4%.
Is The Klinique Medical Clinic PCL's Debt-to-EBITDA too high?
The Klinique Medical Clinic PCL's current Debt-to-EBITDA of 0.65 is 23% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 0.94. The Personal Services industry median Debt-to-EBITDA is 2.32. The Klinique Medical Clinic PCL's value of 0.65 is 72% below this industry median. Based on the distribution chart, The Klinique Medical Clinic PCL ranks #15 out of 70 companies in the Personal Services industry, which is in the top quartile — a strong position relative to peers. Overall, The Klinique Medical Clinic PCL has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Klinique Medical Clinic PCL's Debt-to-EBITDA compare to ROL and SCI?
According to the Personal Services industry distribution chart, The Klinique Medical Clinic PCL ranks #15 out of 70 companies for Debt-to-EBITDA. This places The Klinique Medical Clinic PCL in the top 21% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.32. The Klinique Medical Clinic PCL's value of 0.65 is 72% below this benchmark. Historically, The Klinique Medical Clinic PCL's own Debt-to-EBITDA has ranged from 0.74 to 0.94 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 2.32, The Klinique Medical Clinic PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Personal Services company?
The median Debt-to-EBITDA among Personal Services companies is 2.32, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Klinique Medical Clinic PCL's current Debt-to-EBITDA of 0.65 is 72% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on The Klinique Medical Clinic PCL. For the Personal Services industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Klinique Medical Clinic PCL's current Debt-to-EBITDA is 0.65, which is 23% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Klinique Medical Clinic PCL stock overvalued right now?
Based on GuruFocus' analysis, The Klinique Medical Clinic PCL (BKK:KLINIQ) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿44.59, compared to a current price of ฿28.00 — trading 37.2% below its estimated fair value. The current Debt-to-EBITDA is 0.65, which is 23% below median its 10-year median of 0.84 and 72% below the Personal Services industry median of 2.32. The Klinique Medical Clinic PCL's overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For The Klinique Medical Clinic PCL (BKK:KLINIQ), the current Debt-to-EBITDA is 0.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Klinique Medical Clinic PCL (BKK:KLINIQ) Overvalued in 2026?
Based on GuruFocus' analysis, The Klinique Medical Clinic PCL stock appears to be undervalued.
The current stock price of ฿28.00 is trading 37.2% below its estimated GF Value™ of ฿44.59.
GuruFocus considers The Klinique Medical Clinic PCL to be Significantly Undervalued.
Key valuation signals for BKK:KLINIQ:
Debt-to-EBITDA: 0.65 (23% below median its 10-year median of 0.84)
GF Value™: ฿44.59 vs. price of ฿28.00 (37.2% below fair value)
Industry Position: 72% below the Personal Services median (#15 of 70)
No single metric tells the full story. See the BKK:KLINIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Klinique Medical Clinic PCL provides skin care services, beauty, skin care, body contouring, and surgery. including providing holistic care services. The company has a wide range of services and products to meet the needs of customers at all levels, such as facial treatment services, reducing redness, reducing dark spots, laser services for face lifting, face reshaping, skin care, Body shape by removing and dissolving fat, cosmetic surgery, etc. In addition, the company also sells cosmeceuticals. There are various types of products, such as Special Care, Clean & Prepare, Whitening Set, Sun Care, and Antioxidant. The group operates two core business segments: Skin medical services and distribution of cosmetics and medical cosmetics; and Surgery services.
89GF Score
Get the complete analysis for BKK:KLINIQ
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:KLINIQ has been successfully added to your 
